Daiichi Sankyo and Merck Withdraw Ifinatamab Deruxtecan BLA for Previously Treated Extensive-Stage SCLC
Daiichi Sankyo and Merck withdrew their BLA for ifinatamab deruxtecan in treating extensive-stage small cell lung cancer (ES-SCLC) after the FDA deemed trial data insufficient. The Phase 2 trial showed a 48.2% ORR, but the FDA required more evidence. The companies continue Phase 3 trials and plan to evaluate future regulatory filings based on those results. Ifinatamab deruxtecan is an investigational B7-H3-directed ADC.
How this was made
The 30-second read
Why it matters
Regulatory setback reduces near‑term revenue expectations for both companies and may affect investor sentiment toward ADC programs.
Market read
The withdrawal removes a potential accelerated‑approval product, likely prompting short‑term price declines for both stocks and tempering optimism in the oncology ADC space.
What to watch
Continued Phase 3 enrollment could still deliver positive data that offsets short‑term disappointment.
Background
The article reports the voluntary withdrawal of a U.S. BLA for ifinatamab deruxtecan, an investigational B7‑H3‑directed ADC jointly developed by Daiichi Sankyo and Merck.
Ticker impact
Merck, co‑developer of ifinatamab deruxtecan, saw the joint BLA withdrawn, affecting its oncology pipeline.
downward pressure as the market reassesses future pipeline value
The withdrawal eliminates a potential new indication and may affect upcoming sales forecasts.
Market effects
Setback for the ADC and broader oncology biotech sector, may dampen near‑term optimism.
US biotech indices could see modest pullback; Japanese market may feel secondary effects via Daiichi Sankyo.
Regulatory outcome highlights FDA scrutiny of accelerated approvals for ADCs worldwide.
Counterpoint
The withdrawal may allow more rigorous data collection, potentially leading to a stronger future filing.
Key entities
- companyDaiichi Sankyo
Japanese pharmaceutical firm, US‑listed as DSKX.
- companyMerck
US pharmaceutical giant, ticker MRK.
